Overview

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.
Phase:
Phase 2
Details
Lead Sponsor:
Tasly Pharmaceuticals, Inc.
Treatments:
Cardiotonic Agents